Pathophysiology‐based phenotyping in type 2 diabetes: A clinical classification tool
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Type 2 diabetes may be a more heterogeneous disease than previously thought. Better understanding of pathophysiological subphenotypes could lead to more individualized diabetes treatment. We examined the characteristics of different phenotypes among 5813 Danish patients with new clinically diagnosed type 2 diabetes. Methods: We first identified all patients with rare subtypes of diabetes, latent autoimmune diabetes of adults (LADA), secondary diabetes, or glucocorticoid‐associated diabetes. We then used the homeostatic assessment model to subphenotype all remaining patients into insulinopenic (high insulin sensitivity and low beta cell function), classical (low insulin sensitivity and low beta cell function), or hyperinsulinemic (low insulin sensitivity and high beta cell function) type 2 diabetes. Results: Among 5813 patients diagnosed with incident type 2 diabetes in the community clinical setting, 0.4% had rare subtypes of diabetes, 2.8% had LADA, 0.7% had secondary diabetes, 2.4% had glucocorticoid‐associated diabetes, and 93.7% had WHO‐defined type 2 diabetes. In the latter group, 9.7% had insulinopenic, 63.1% had classical, and 27.2% had hyperinsulinemic type 2 diabetes. Classical patients were obese (median waist 105 cm), and 20.5% had cardiovascular disease (CVD) at diagnosis, while insulinopenic patients were fairly lean (waist 92 cm) and 17.5% had CVD (P = 0.14 vs classical diabetes). Hyperinsulinemic patients were severely obese (waist 112 cm), and 25.5% had CVD (P < 0.0001 vs classical diabetes). Conclusions: Patients clinically diagnosed with type 2 diabetes are a heterogeneous group. In the future, targeted treatment based on pathophysiological characteristics rather than the current “one size fits all” approach may improve patient prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Calculation of HOMA2 may be helpful in daily clinical practice because it is inexpensive, easy to perform, and correlates reasonably well with hyperinsulinemic clamp data.(61,62) HOMA2S is a measure of IS in both peripheral and liver tissue,(62) and our HOMA2S‐based analysis showing that 10% of newly diagnosed type 2…”
ResultThe Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I. R., Shattock, M., Bottazzo, G. F., & Holman, R. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03062-6 · Cited by 779
Cnop, M., Landchild, M. J., Vidal, J., Havel, P. J., Knowles, N. G., Carr, D. R., Wang, F., Hull, R. L., Boyko, E. J., Retzlaff, B. M., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1005 · Cited by 432
Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype
Hawa, M. I., Kolb, H., Schloot, N., Beyan, H., Paschou, S. A., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Beck-Neilsen, H., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0931 · Cited by 339
Buzzetti, R., Di Pietro, S., Giaccari, A., Petrone, A., Locatelli, M., Suraci, C., Capizzi, M., Arpi, M. L., Bazzigaluppi, E., Dotta, F., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1696 · Cited by 242
Costanzo, P., Cleland, J. G. F., Pellicori, P., Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J., & Atkin, S. L. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1551 · Cited by 199 · cited 1×
“CVD(43) and is possible a main mediator of the higher cardiovascular occurrence in hyperinsulinemic patients, although the association with obesity is complex in patients with type 2 diabetes.(44,45) As the cause‐ and‐effect directions in the pathophysiological pathways of obesity and IR are impossible to disentangle…”
BackgroundLow levels of C‐peptide have clinical significance for established Type 1 diabetes
Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold, P., Burger, D., Zheng, H., & Faustman, D. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12850 · Cited by 131
Cited by
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes
Wagner, R., Heni, M., Tabák, A. G., Machann, J., Schick, F., Randrianarisoa, E., Hrabě de Angelis, M., Birkenfeld, A. L., Stefan, N., Peter, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1116-9 · Cited by 415
Phenotypic and genetic classification of diabetes
Deutsch, A. J., Ahlqvist, E., & Udler, M. S. (2022) · Diabetologia · doi:10.1007/s00125-022-05769-4 · Cited by 108
Kabisch, S., Meyer, N. M. T., Honsek, C., Gerbracht, C., Dambeck, U., Kemper, M., Osterhoff, M. A., Birkenfeld, A. L., Arafat, A. M., Hjorth, M. F., et al. (2019) · Nutrients · doi:10.3390/nu11102385 · Cited by 38
Kabisch, S., Meyer, N. M. T., Honsek, C., Gerbracht, C., Dambeck, U., Kemper, M., Osterhoff, M. A., Birkenfeld, A. L., Arafat, A. M., Weickert, M. O., et al. (2019) · Nutrients · doi:10.3390/nu11112726 · Cited by 20
“Despite having low amounts of visceral and hepatic fat, these patients are at high risk for long-term complications [19,20,49].”
Background
Metadata
- Authors
- Stidsen, J. V., Henriksen, J. E., Olsen, M. H., Thomsen, R. W., Nielsen, J. S., Rungby, J., Ulrichsen, S. P., Berencsi, K., Kahlert, J. A., Friborg, S. G., Brandslund, I., Nielsen, A. A., Christiansen, J. S., Sørensen, H. T., Olesen, T. B., & Beck‐Nielsen, H.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2018-04-26
- Volume
- 34
- Issue
- 5
- Pages
- e3005-e3005
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2800776805
- Cited by
- 72
- References
- 13
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathophysiology‐based phenotyping in type 2 diabetes: A clinical classification tool. https://app.cochat.ai/papers/10.1002/dmrr.3005
- The paper
- Stidsen, J. V., Henriksen, J. E., Olsen, M. H., Thomsen, R. W., Nielsen, J. S., Rungby, J., Ulrichsen, S. P., Berencsi, K., Kahlert, J. A., Friborg, S. G., Brandslund, I., Nielsen, A. A., Christiansen, J. S., Sørensen, H. T., Olesen, T. B., & Beck‐Nielsen, H. (2018). Pathophysiology‐based phenotyping in type 2 diabetes: A clinical classification tool. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.